Reversible dilated cardiomyopathy related to amphotericin B therapy.
We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.
Danaher
Patrick J
PJ
Department of Infectious Diseases, David Grant USAF Medical Center, Travis AFB, CA 94535, USA. patrick.danaher@60mdg.travis.af.mil
Cao
Michael K
MK
Anstead
Gregory M
GM
Dolan
Matthew J
MJ
DeWitt
Caroline C
CC
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000139:chemically induced*; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004338:Drug Combinations; D004452:Echocardiography; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B